NCT01272206已完成1 期
A Single-centre, Randomised, Double-blind, Single Dose, Cross-over Trial Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021, Following Intravenous Administration in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 主要终点
- Frequency of adverse events (AEs)
研究概览
简要总结
This trial is conducted in Europe. The aim of this trial is to investigate the safety and pharmacokinetics (the rate at which the body eliminates the trial drug) of NNC 0128-0000-2011 compared to NNC 0128-0000-2021 when given for the first time to healthy human subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Body weight between 50.0 and 100.0 kg, both inclusive
- •Body mass index (BMI) between 18.0 and 28.0 kg/m2, both inclusive
排除标准
- •Known or suspected hypersensitivity to trial product or related products, such as activated recombinant factor VII
- •Any clinical sign or known history of atherosclerosis or thromboembolic events
- •Renal dysfunction
- •A subject considered at high risk of thromboembolic events
- •Overt bleeding, including from gastrointestinal tract
- •Hepatitis B or C infection
- •Human immunodeficiency virus (HIV) infection
- •Positive test for drugs of abuse or alcohol as well as a history of alcohol or drug abuse within the past 12 months
- •Smoking within 3 months prior to trial start
- •Unable to abstain from alcohol consumption during visits of trial product administration, visit 2 (0-28 days after screening) and visit 3 (2-4 weeks after visit 2)
- •Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the investigator (trial physician)
- •Excessive consumption of a diet deviating from a normal diet
- •Blood donation within the last three months prior to screening
- •The receipt of any investigational product within 30 days of trial product administration
- •Participation in any other trial investigating a procoagulant within the last six months prior to screening
- •Strenuous exercise within four days prior trial start
- •Suffers from a life threatening disease
- •Males who are sexually active and not surgically sterilised, who or whose partner are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practise).
- •Subjects at increased cardiovascular risk, including a strong family history of cardiovascular disease
- •Subjects with high fasting cholesterol at trial start
研究组 & 干预措施
A
Experimental
干预措施: NNC 0128-0000-2011 (Drug)
B
Experimental
干预措施: NNC 0128-0000-2021 (Drug)
结局指标
主要结局
Frequency of adverse events (AEs)
时间窗: from first trial product administration until maximally 10 weeks after last trial product administration
次要结局
- Neutralising antibodies against FVII and/or N7-GP(from first trial product administration until maximally 10 weeks after last trial product administration)
研究者
相似试验
已完成
2 期
Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01697618Novo Nordisk A/S13
已完成
1 期
A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male VolunteersCongenital Bleeding DisorderHaemophilia AHaemophilia BHealthyNCT00951873Novo Nordisk A/S38
已完成
2 期
Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)InflammationRheumatoid ArthritisNCT01181050Janssen Research & Development, LLC63
已完成
1 期
A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male SubjectsDiabetes Mellitus, Type 2DiabetesNCT00813020Novo Nordisk A/S44
已完成
1 期
Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy VolunteersCongenital Bleeding DisorderCongenital FXIII DeficiencyHealthyNCT01847989Novo Nordisk A/S50